Independent reference. Not affiliated with, endorsed by, or speaking for the U.S. Food and Drug Administration.
FDA Medication Tracker

← All approvals · Other · 2025

Gomekli (mirdametinib)

The FDA approved Gomekli (mirdametinib) on February 11, 2025 to treat neurofibromatosis type 1 who have symptomatic plexiform neurofibromas not amenable to complete resection.
Brand name
Gomekli
Generic name
mirdametinib
FDA approval date
February 11, 2025
Approved use (FDA wording)
To treat neurofibromatosis type 1 who have symptomatic plexiform neurofibromas not amenable to complete resection
Category on this site
Other

Official sources

Facts only. This site lists what the FDA has approved and what the FDA says each drug is approved for, quoted or closely paraphrased from FDA and openFDA records. It gives no medical advice, no dosing, and no comparisons, and it says nothing about whether a drug is right for anyone. Talk to a licensed clinician about any medication. Records can lag or contain errors; the FDA's own pages are authoritative.